Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes

NCT04183868 is registered in ClinicalTrials.gov with University of Catanzaro as lead sponsor.

NCT NCT04183868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04183868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes
Lead sponsor
University of Catanzaro
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2016
Completion date
October 31, 2021
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular risk factor, type 2 diabetes